Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials.

ABSTRACT:

Background

Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key treatments for many cancers; however, monotherapies with PD-1/PD-L-1 inhibitors (PD-1i) have shown a limited efficacy in MM patients. We conducted a meta-analysis to evaluate the safety and efficacy of PD-1i in combination with standard of care (SOC) therapies for MM.

Methods

A systematic search identified phase II and III randomized clinical trials involving MM patients treated with PD-1i, using terms such as "Relapsed Multiple Myeloma" and "PD-1 inhibitors." The search included trials published in English after 2016 using the PubMed, CINAHL, and Cochrane databases. Data were analyzed using RStudio v

SUBMITTER: Alsaddi Z 

PROVIDER: S-EPMC12691222 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature